SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended
dose of ganetespib when administered in combination with sirolimus in patients with
refractory or relapsed sarcomas including unresectable or metastatic sporadic or
neurofibromatosis type 1 (NF1) associated MPNST. Phase I enrollment has been closed.
Phase 2: To determine the clinical benefit of ganetespib in combination with sirolimus for
patients with unresectable or metastatic sporadic or NF1 associated MPNST.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborators:
Synta Pharmaceuticals Corp. United States Department of Defense